Ask AI
BTKi Use and Sequencing in CLL

CE / CME

From the APP Perspective: Expert Insights Into BTK Inhibitor Optimization and Sequencing in Chronic Lymphocytic Leukemia

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Released: November 05, 2025

Expiration: May 04, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 68-year-old woman with CLL harboring del(17p) received triplet therapy with venetoclax, acalabrutinib, and obinutuzumab, achieving a partial remission with persistent MRD. Eighteen months later, she presents with progressive disease, and NGS reveals an acquired BTK C481S mutation.

Considering available information, which of the following is the best next-line of therapy for this patient?